Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Hyperactive mTORC1 in lung mesenchyme induces endothelial cell dysfunction and pulmonary vascular remodeling
Susan M. Lin, … , Jillian F. Evans, Vera P. Krymskaya
Susan M. Lin, … , Jillian F. Evans, Vera P. Krymskaya
Published December 21, 2023
Citation Information: J Clin Invest. 2024;134(4):e172116. https://doi.org/10.1172/JCI172116.
View: Text | PDF
Research Article Cell biology Vascular biology Article has an altmetric score of 6

Hyperactive mTORC1 in lung mesenchyme induces endothelial cell dysfunction and pulmonary vascular remodeling

  • Text
  • PDF
Abstract

Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease caused by tuberous sclerosis complex 1/2 (TSC1/2) gene mutations in pulmonary mesenchymal cells, resulting in activation of the mechanistic target of rapamycin complex 1 (mTORC1). A subset of patients with LAM develop pulmonary vascular remodeling and pulmonary hypertension. Little, however, is known regarding how LAM cells communicate with endothelial cells (ECs) to trigger vascular remodeling. In end-stage LAM lung explants, we identified EC dysfunction characterized by increased EC proliferation and migration, defective angiogenesis, and dysmorphic endothelial tube network formation. To model LAM disease, we used an mTORC1 gain-of-function mouse model with a Tsc2 KO (Tsc2KO) specific to lung mesenchyme (Tbx4LME-Cre Tsc2fl/fl), similar to the mesenchyme-specific genetic alterations seen in human disease. As early as 8 weeks of age, ECs from mice exhibited marked transcriptomic changes despite an absence of morphological changes to the distal lung microvasculature. In contrast, 1-year-old Tbx4LME-Cre Tsc2fl/fl mice spontaneously developed pulmonary vascular remodeling with increased medial thickness. Single-cell RNA-Seq of 1-year-old mouse lung cells identified paracrine ligands originating from Tsc2KO mesenchyme, which can signal through receptors in arterial ECs. These ECs had transcriptionally altered genes including those in pathways associated with blood vessel remodeling. The proposed pathophysiologic mesenchymal ligand–EC receptor crosstalk highlights the importance of an altered mesenchymal cell/EC axis in LAM and other hyperactive mTORC1–driven diseases. Since ECs in patients with LAM and in Tbx4LME-Cre Tsc2fl/fl mice did not harbor TSC2 mutations, our study demonstrates that constitutively active mTORC1 lung mesenchymal cells orchestrated dysfunctional EC responses that contributed to pulmonary vascular remodeling.

Authors

Susan M. Lin, Ryan Rue, Alexander R. Mukhitov, Akansha Goel, Maria C. Basil, Kseniya Obraztsova, Apoorva Babu, Slaven Crnkovic, Owen A. Ledwell, Laura T. Ferguson, Joseph D. Planer, Ana N. Nottingham, Kanth Swaroop Vanka, Carly J. Smith, Edward Cantu III, Grazyna Kwapiszewska, Edward E. Morrisey, Jillian F. Evans, Vera P. Krymskaya

×

Figure 1

Characterization of pulmonary ECs from patients with LAM.

Options: View larger image (or click on image) Download as PowerPoint
Characterization of pulmonary ECs from patients with LAM.
Representative...
Representative images of H&E- and immunofluorescence-stained LAM lung (n = 3) compared with age- and sex-matched control human lung (n = 3) showing (A) remodeled distal vasculature detected with antibodies against vWF (red) and αSMA (green) and (B) increased intimal fibrosis and medial thickening by H&E staining. DAPI was used to detect nuclei (blue). Scale bars: 50 μm and 100 μm. Insets: Original magnification, ×2. (C) Representative images of dual immunofluorescence staining of human LAM lung (n = 3) demonstrating loss of TSC2 (tuberin, magenta) expression in a LAM lesion and concurrent activation of pS6 (marker of mTOR activation, green) and DAPI (nuclei, blue). White asterisks show LAM micronodules. Scale bars: 50 μm and 100 μm. (D) Representative images of positive immunoreactivity for TSC2 protein (tuberin, magenta) and vWF (green) in ECs lining the pulmonary vasculature in both human control (n = 4) and LAM lungs (n = 4). DAPI (nuclei, blue). Scale bars: 25 μm and 50 μm. (E) LAM and control pulmonary ECs labeled with antibodies against endothelial marker vWF (green) and F-actin (rhodamine phalloidin; red). Nuclei were counterstained with DAPI (blue). Scale bars: 50 μm. (F) Proliferation of control and LAM ECs over 48 hours using a crystal violet growth assay. (G) Representative images of migration of control (n = 5) and LAM (n = 5) ECs following a Boyden chamber assay. (H) Statistical analysis of EC migration quantified 24 hours after migration using 2-tailed t tests of crystal violet absorbence. (I) Representative image of in vitro angiogenesis in 2D of control (n = 6) and LAM (n = 6) ECs. (J) Total tube lengths at 24 hours of growth on Matrigel were analyzed using the Angiogenesis Analyzer plugin in ImageJ (NIH). Data are presented as the mean ± SEM. **P < 0.01 and ***P < 0.001, by 2-tailed t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 8 X users
9 readers on Mendeley
See more details